Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolution and treatment of idiopathic pulmonary fibrosis.
Torrisi SE, Kahn N, Vancheri C, Kreuter M. Torrisi SE, et al. Among authors: kreuter m. Presse Med. 2020 Jun;49(2):104025. doi: 10.1016/j.lpm.2020.104025. Epub 2020 May 11. Presse Med. 2020. PMID: 32437841 Review.
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, Groves R, Hellström PM, Kreuter M, Maher TM, Molina-Molina M, Nordlind K, Sarafidis A, Vancheri C. Costabel U, et al. Among authors: kreuter m. Adv Ther. 2014 Apr;31(4):375-91. doi: 10.1007/s12325-014-0112-1. Epub 2014 Mar 18. Adv Ther. 2014. PMID: 24639005 Free PMC article. Review.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.
IPF, comorbidities and management implications.
Vancheri C, Cottin V, Kreuter M, Hilberg O. Vancheri C, et al. Among authors: kreuter m. Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 3;32 Suppl 1:17-23. Sarcoidosis Vasc Diffuse Lung Dis. 2015. PMID: 26237439 Review.
C-proSP-B: A Possible Biomarker for Pulmonary Diseases?
Kahn N, Rossler AK, Hornemann K, Muley T, Grünig E, Schmidt W, Herth FJF, Kreuter M. Kahn N, et al. Among authors: kreuter m. Respiration. 2018;96(2):117-126. doi: 10.1159/000488245. Epub 2018 May 15. Respiration. 2018. PMID: 29763900 Free article.
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M. Crestani B, et al. Among authors: kreuter m. Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14. Lancet Respir Med. 2019. PMID: 30224318 Clinical Trial.
623 results